300254 Stock Overview
Engages in the research, development, production, and sale of medicine and health food products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ShanXi C&Y Pharmaceutical Group Co.,LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.93 |
| 52 Week High | CN¥11.86 |
| 52 Week Low | CN¥4.98 |
| Beta | 0.23 |
| 1 Month Change | 0.22% |
| 3 Month Change | 14.93% |
| 1 Year Change | -7.08% |
| 3 Year Change | 6.06% |
| 5 Year Change | 11.35% |
| Change since IPO | -23.55% |
Recent News & Updates
Recent updates
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet
Sep 30
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06Shareholder Returns
| 300254 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -7.9% | -1.9% | -1.2% |
| 1Y | -7.1% | -1.8% | 11.8% |
Return vs Industry: 300254 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 300254 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 300254 volatility | |
|---|---|
| 300254 Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300254 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300254's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,234 | Qun Zhao | www.cy-pharm.com |
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product.
ShanXi C&Y Pharmaceutical Group Co.,LTD. Fundamentals Summary
| 300254 fundamental statistics | |
|---|---|
| Market cap | CN¥2.22b |
| Earnings (TTM) | CN¥83.04m |
| Revenue (TTM) | CN¥836.18m |
26.7x
P/E Ratio2.7x
P/S RatioIs 300254 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300254 income statement (TTM) | |
|---|---|
| Revenue | CN¥836.18m |
| Cost of Revenue | CN¥275.04m |
| Gross Profit | CN¥561.14m |
| Other Expenses | CN¥478.10m |
| Earnings | CN¥83.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.33 |
| Gross Margin | 67.11% |
| Net Profit Margin | 9.93% |
| Debt/Equity Ratio | 14.8% |
How did 300254 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 20:15 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ShanXi C&Y Pharmaceutical Group Co.,LTD. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Jun Ling | Ping An Securities Co. Ltd. |
| Xiao Peng | TX Investment Consulting Co., Ltd. |